Some states, like Vermont, are considering expanding access to care with savings from “disease management.” Unfortunately, the CBO found that there is no evidence that disease management saves money. After taking into account the cost of running the program (often subcontracted to a drug company spin-off) disease management may actually raise costs, as it did in the Florida Medicaid program.
